255 related articles for article (PubMed ID: 33431401)
1. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
[No Abstract] [Full Text] [Related]
2. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
Iheanacho T; Payne K; Tsai J
Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
4. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
5. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
6. Low-Barrier Buprenorphine Treatment for People Experiencing Homelessness.
Gibson CL; Lo E
Psychiatr Serv; 2023 Jan; 74(1):104. PubMed ID: 36254451
[No Abstract] [Full Text] [Related]
7. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
Narayan A; Balkrishnan R
Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
[TBL] [Abstract][Full Text] [Related]
8. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
[TBL] [Abstract][Full Text] [Related]
9. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
10. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
11. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
12. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine Opioid Treatment During the COVID-19 Pandemic.
Luigi M; Luo M; Maes EJP
JAMA Intern Med; 2021 Aug; 181(8):1135. PubMed ID: 33843962
[No Abstract] [Full Text] [Related]
14. Access to treatment for opioid use disorders: Medical student preparation.
McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.
Nguyen TD; Saloner B; Stein BD
JAMA Intern Med; 2021 Aug; 181(8):1135-1136. PubMed ID: 33843947
[No Abstract] [Full Text] [Related]
16. Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals.
Morgan JR; Leech AA
Addiction; 2024 Jun; 119(6):1123-1124. PubMed ID: 38570825
[No Abstract] [Full Text] [Related]
17. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
18. A Mobile Buprenorphine Treatment Program for Homeless Patients With Opioid Use Disorder.
Buzza C; Elser A; Seal J
Psychiatr Serv; 2019 Jul; 70(7):635-636. PubMed ID: 31258036
[No Abstract] [Full Text] [Related]
19. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Bachireddy C; Terplan M
Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
[TBL] [Abstract][Full Text] [Related]
20. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
Berry ARW; Finlayson TL; Mellis LM; Urada LA
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
